CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn
Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.
Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL
Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.
CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management
Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.
MCL Treatment Armamentarium Transforms With BTK Inhibitors, CAR T-Cell Addition
Peter Martin, MD, provides an overview of what the current MCL treatment paradigm looks like as well as areas of future exploration and debate.
Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies
Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.
Expert Shares Efforts to Expand Use of CAR T-Cell Therapy to Solid Tumors
Natalie Sophia Grover, MD, discusses ongoing research with CAR T-cell therapy in hematologic malignancies, efforts examining the potential for this approach in solid tumors, and future directions and challenges with this modality.
Berdeja Projects Promising Future for JNJ-4528 in Relapsed/Refractory Myeloma
Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.
Novel Off-the-Shelf CAR-NK Therapy FT596 Shows Early Promise in B-Cell Malignancies
Bob Valamehr, PhD, discusses the process by which a targeted CAR natural-killer cell product is engineered as well as how it will be examined in future research efforts.
Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances
Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.
Cell-Free DNA Shows Potential in Identifying Transformed Castration-Resistant Neuroendocrine Prostate Cancer
Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.
CAR-T Leads Advances Across Lymphomas, But Further Research Needed
Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.
CD19-Directed CAR-NK Cell Therapy Elicits Responses in Non-Hodgkin Lymphoma and CLL
Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.
CTC Detection Linked to Relapse in Stage III Melanoma
The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.
CAR-T, Novel Combos Continue to Show Benefit in Multiple Myeloma
Larry Anderson, MD, PhD, discusses emerging therapies for patients with multiple myeloma that were highlighted at the 2019 ASH Annual Meeting.
BiTEs, CAR T-Cell Therapy Enhance ALL Armamentarium, But Questions Remain
Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.
2 Clarke Drive Cranbury, NJ 08512